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SUMMARY
Background—Adjuvant chemotherapy for resected early stage NSCLC provides modest 
survival benefit. Bevacizumab, a monoclonal antibody directed against vascular endothelial growth 
factor, improves outcomes when added to platinum-based chemotherapy in advanced stage non-
squamous NSCLC. We conducted a phase III study to evaluate the addition of bevacizumab to 
adjuvant chemotherapy in early stage resected NSCLC (E1505). The primary endpoint was overall 
survival.
Methods—Adult patients (≥ 18 years old) with ECOG performance status 0 or 1 with completely 
resected stage IB (≥4 centimeters) to IIIA (AJCC 6th edition) NSCLC were enrolled within 6–12 
weeks of surgery and stratified by chemotherapy regimen, stage, histology, and sex. Minimum 
mediastinal lymph node sampling at specified levels was required (level 7 and 4 for right-sided 
tumors or level 7 and 5 and/or 6 for left-sided tumors). Normal laboratory values within two weeks 
of randomisation were required for enrollment. Chemotherapy, which was selected for each patient 
prior to randomisation, consisted of four, 3-week (21-day) cycles of cisplatin (75 mg/m2 in all 
regimens) with either vinorelbine 30 mg/m2 days 1 and 8; docetaxel 75 mg/m2 day 1; OR 
gemcitabine 1200 mg/m2 days 1 and 8; OR, starting in 2009 with an amendment, pemetrexed 500 
mg/m2 day 1 along with B12 and folic acid supplementation. Patients were randomised 1:1 to Arm 
A (chemotherapy) or Arm B, adding bevacizumab at 15 mg/kg every 3 weeks starting with cycle 1 
of chemotherapy and continuing for one year. Randomisation to treatment arm was performed 
centrally and determined using permuted blocks within strata with dynamic balancing on 
institution. The study had 85% power to detect a 21% reduction in the overall survival (OS) hazard 
rate with a one-sided 0·025-level test. The primary endpoint was overall survival, which was 
defined as the time from randomisation to death from any cause, and patients who were thought to 
be alive at the time of final analysis were censored at the last date of contact with analysis done 
based on intention to treat. This is final analysis of the primary endpoint of overall survival of 
E1505 (NCT00324805).
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Findings—From July 2007 to September 2013, 1501 patients were enrolled, of whom 26% 
(N=383) had stage IB, 44% (N=636) stage II, and 30% (N=439) stage IIIA) with 28% (N=422) 
squamous cell histology. Cisplatin-based chemotherapy regimens utilized were vinorelbine 25% 
(N=377), docetaxel 23% (N=343), gemcitabine 19% (N=283), and pemetrexed 33% (N=497). At a 
median follow-up time of 50·3 months (IQR 32.9–68.0), estimated OS hazard ratio (B/A) was 0·99 
(95% CI: 0·82–1·19, p=0·90). The median OS on Arm A has not been reached and is 85.8 months 
(95% CI 74.9-NA) on Arm B. Statistically significantly increased grade 3–5 toxicities of note (all 
attributions) included: overall worst grade (ie all grade 3/4/5 toxicities) (67%(N=496) versus 83%
(N=610)); hypertension (8%(N=60) versus 30%(N=219)), and neutropenia (33%(N=241) versus 
37%(N=275)) on Arms A and B, respectively. There was no significant difference in grade 5 
adverse events per arm (N=15 on arm A and N=19 on arm B).
Interpretation—The addition of bevacizumab to adjuvant chemotherapy failed to improve 
overall survival for patients with surgically resected early stage NSCLC. Bevacizumab does not 
have a role in this setting and should not be considered as an adjuvant therapy for resected NSCLC 
patients.
Funding—This study was coordinated by the ECOG-ACRIN Cancer Research Group and 
supported by the National Cancer Institute of the National Institutes of Health.
INTRODUCTION
Complete surgical resection remains the most effective initial therapy for patients with early 
stage non-small cell lung cancer (NSCLC). Adjuvant chemotherapy became a standard after 
the 2003 presentation of the International Adjuvant Lung Cancer Trial (IALT) (n=1,867)1 
with a reported 4% absolute five-year survival benefit and an overall survival hazard ratio 
(OS HR) =0·86 (95% CI: 0·76–0·98, P<0·03) in favor of adjuvant cisplatin-based 
chemotherapy for 4 cycles. Two other positive adjuvant chemotherapy trials, which utilized 
only cisplatin with vinorelbine, maintained significantly improved survival benefits with 
long-term follow-up.2,3 More specifically, the ANITA trial, which included a mix of stage 
IB, II and IIIA patients, reported a median overall survival of 65·7 months (95% CI 47·9–
88·5) in the chemotherapy arm compared to 43·7 months (95% CI 35·7–52·3) with 
observation.4 Meta-analyses of NSCLC adjuvant chemotherapy trials confirmed the 4–5% 
absolute survival increase at 5 years.5,6 Thus, current guidelines endorse the use of adjuvant 
cisplatin-based chemotherapy for stage II and IIIA NSCLC after complete resection.7,8 
Adjuvant cisplatin-based chemotherapy doublets for stage I patients is often suggested for 
patients with larger stage I (N0) tumors at ≥ 4 centimeters based on improved survival in 
subset analyses from the earlier adjuvant trials.3,9
In the setting of advanced stage NSCLC, the first agent to improve survival when added to a 
platinum doublet was bevacizumab. Bevacizumab, a monoclonal antibody directed against 
vascular endothelial growth factor (VEGF), improved response, progression-free survival, 
and overall survival when added to carboplatin/paclitaxel in advanced stage non-squamous 
NSCLC in the E4599 trial.10 Based on those positive results, this phase III trial (E1505) was 
designed to assess whether the addition of bevacizumab to cisplatin-based chemotherapy 
would improve survival of patients with resected early stage NSCLC in the adjuvant setting, 
who despite adjuvant chemotherapy remain at high risk of relapse.
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In the LACE meta-analysis of adjuvant chemotherapy trials, cisplatin/vinorelbine was 
associated with a superior survival benefit compared to the other regimens.11 In addition to 
cisplatin/vinorelbine we decided to include other standard cisplatin-based doublet regimens 
utilized for stage IV NSCLC in E1505, including cisplatin/gemcitabine and cisplatin/
docetaxel given their efficacy in the metastatic setting and practice patterns. In 2009 
cisplatin/pemetrexed was also included in E1505 for non-squamous patients following FDA 
approval of that regimen in advanced NSCLC. Subsequently a phase II trial that 
demonstrated that cisplatin/pemetrexed was better tolerated than cisplatin/vinorelbine in the 
adjuvant setting.12 Patients with squamous histology were included in E1505, based on the 
assumption that the hemoptysis seen more frequently with bevacizumab in metastatic 
squamous lung cancer patients would be unlikely in patients post-resection. However, 
patients with squamous histology were not permitted to receive adjuvant pemetrexed/
cisplatin based on inferior outcomes with this regimen in advanced stage squamous lung 
carcinoma patients.
METHODS
Study design and participants
This open-label predominantly North American Intergroup phase III trial was led by the 
ECOG-ACRIN Cancer Research Group coordinating center and approved by the ethics 
committee of every participating center and undertaken according to the Declaration of 
Helsinki. All patients gave written informed consent prior to participation. Eligible patients 
had undergone complete resection of stage IB (≥ 4 centimeters), II or IIIA NSCLC no less 
than 6 weeks and no more than 12 weeks prior to enrollment and had recovered from 
surgery. Staging was completed per AJCC 6th edition. Mediastinal lymph node sampling at 
specified levels was required (level 7 and 4 for right-sided tumors or level 7 and 5 and/or 6 
for left-sided tumors). Patients were at least 18 years old with ECOG performance status 0 
or 1. No prior systemic chemotherapy was allowed but patients with a prior cured 
malignancy treated with surgery, biologic, or hormonal cancer therapy or radiation therapy 
was allowed if all treatment was completed at least 5 years prior to randomisation. Normal 
laboratory values within two weeks of randomisation were required including platelet and 
neutrophil counts within normal limits (WNL), normal coagulation studies, liver function 
within 5 times the upper limit of normal (ULN), adequate renal function (creatinine no more 
than 1·5 times ULN), and urine protein creatinine spot test WNL or validated with a 24-hour 
urine collection. Patients assigned to pemetrexed/cisplatin were also required to have a 
calculated creatinine clearance ≥ 45mL/min using the standard Cockcroft and Gault formula. 
Patients were excluded for active arterial thrombotic disease (including myocardial 
infarction) within 12 months prior to randomisation. Patients with any history of cerebral 
vascular accident (CVA) or transient ischemic attack (TIA) were excluded. All women of 
childbearing potential had a negative pregnancy test within 2 weeks prior to randomisation 
and both fertile men and women must have agreed to use adequate contraceptive measures 
during study treatment. Patients must not have had any clinically significant ongoing, active, 
or serious infection; symptomatic or uncontrolled congestive heart failure; symptomatic or 
uncontrolled cardiac arrhythmia; or any other medical condition or psychiatric illness/social 
situations that would limit compliance with study requirements.
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Patients were excluded for history of bleeding diathesis or coagulopathy; uncontrolled 
hypertension; use of dipyridamole, ticlopine, clopidogrel, and/or cilostazol; serious non-
healing wound, ulcer, bone fracture, or having undergone a major surgical procedure, open 
biopsy, or significant traumatic injury within 28 days prior to randomisation OR core biopsy 
within 7 days prior to randomisation. Patients were excluded for any abdominal abscess or 
perforation within 28 days of randomisation or anticipated surgery during course of the 
study, or ongoing post-operative hemoptysis.
Randomisation and masking
Randomisation was performed using permuted blocks within strata with dynamic balancing 
on main ECOG-ACRIN institutions plus affiliates. The randomisation was stratified based 
on the patients planned chemotherapy (cisplatin/vinorelbine, cisplatin/docetaxel, cisplatin/
gemcitabine, cisplatin/pemetrexed); stage of disease (IB (>=4cm), II, IIIA-N2, IIIA-T3N1); 
histology (squamous cell, other NSCLC) and gender (male or female). No masking was 
performed and all patients and care team members were aware of treatment assignments. 
The only masking that occurred was during Data Safety and Monitoring Committee 
(DSMC) meetings during which the DSMC was blinded to treatment arm during 
assessments of efficacy and toxicity at the pre-defined analysis time points.
Procedures
All patients were to receive up to 4 cycles of 21 days of cisplatin given at 75 mg/m2 on day 
1, in combination with a third generation cytotoxic agent. The other chemotherapy agents 
based on investigator’s choice were: vinorelbine 30 mg/m2 days 1 and 8; docetaxel 75 
mg/m2 day 1; gemcitabine 1200 mg/m2 days 1 and 8; and starting in 2009 with an 
amendment, pemetrexed 500 mg/m2 day 1 along with B12 (1000 micrograms 
intramuscularly at least every 9 weeks while on therapy starting at a minimum on the first 
day of therapy and folic acid supplementation (at 400 micrograms daily orally). The 
investigator was required to indicate the selected chemotherapy regimen for the patient prior 
to randomisation. Patients randomised to Arm B also received bevacizumab administered 
with chemotherapy for a total of 4 cycles and continued every 21 days for up to 1 year 
(measured from first day of protocol treatment). Bevacizumab was dosed at 15 mg/kg IV on 
day 1 of each cycle.
Dose interruptions and dose reductions for the chemotherapy drugs followed standard 
practice guidelines. If a dose delay was required for 1 drug, both chemotherapy drugs (and 
bevacizumab for arm B) were delayed and resumed together so that they remained in sync. 
Day 1 chemotherapy could only be administered for absolute neutrophil count of at least 
1,500/mm2 and platelet count of at least 100,000/Ul. Treatment could be delayed for up to 3 
weeks to allow for recovery of counts. If febrile neutropenia was documented cisplatin doses 
were not adjusted, but vinorelbine, docetaxel, gemcitabine or pemetrexed were reduced by 1 
dose level for first event and by 2 dose levels for the 2nd episode and protocol chemotherapy 
was discontinued for a third episode. Dose level 1 was 25% of original dosing and dose level 
2 was 50% of original dosing. Cisplatin dose reductions by 25% were permitted for grade 3 
nausea/vomiting despite maximum supportive care or grade 3 oral mucositis. Cisplatin was 
reduced by 50% for creatinine of >1.5–2.0 times the upper limit of normal (ULN) and held 
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if > 2.0 times the ULN, but could be restarted with 25% reduction if the creatinine improved 
within 3 weeks. Both chemotherapeutic agents were held for sensory/motor neuropathy or 
grade 2 or higher and resumed after recovery to grade 1 (with 25% reduction if max grade 
was 2 and 50% reduction if maximum grade was 3 or higher). Cisplatin was discontinued for 
grade 3 or 4 hearing loss. For hepatic toxicity: vinorelbine or docetaxel or pemetrexed was 
reduced by 25% for grade 2 hepatic toxicity and held for grade 3 or higher with resumption 
only if recovery within 3 weeks. For any clinically significant grade 3 or 4 toxicity felt to be 
related to chemotherapy the treatment was delayed until recovery to at least grade 1, then 
resumed with a 25% dose reduction in the agent felt most likely to have caused the toxicity. 
Further dose reductions were permitted per investigator discretion and discontinuation of 
protocol chemotherapy was required if such toxicity did not resolve to at least grade 1 within 
3 weeks. For patients on arm B, continuation of bevacizumab was permitted despite early 
discontinuation of chemotherapy.
Particular for docetaxel, if an allergic reaction/anaphylaxis event occurred, the drug was 
stopped and diphehydramine and dexamethasone were given with a resumption of a slower 
infusion. If the symptoms recurred then docetaxel was discontinued. In such instances, after 
discussion with study chair, the patient was permitted to switch to another chemotherapy 
arm, or if on arm B could continue on bevacizumab alone. For Day 8; vinorelbine or 
gemcitabine were reduced to 75% dose for ANC of 500–999 × 106/L or platelet count of 
50,000–74,999 × 106/L or held for lower results of either ANC or platelets.
Patients continued protocol therapy up to 4 cycles of chemotherapy and, for those on arm B, 
up to 1 year of bevacizumab (counted from first day of therapy) unless there was evidence of 
recurrent NSCLC, development of second primary cancer (excluding non-melanoma skin 
cancer or carcinoma in situ of the cervix), or in the situation that continuation on protocol 
was felt to be detrimental to the patient’s health due to extraordinary medical circumstances.
Bevacizumab was never dose reduced, but was to be delayed if chemotherapy was delayed 
to allow for same day administration. If chemotherapy was withheld (skipped) bevacizumab 
was given on schedule. Bevacizumab was discontinued for hemoptysis of > grade 1, grade 3 
or 4 congestive heart failure, evidence of reversible posterior leukoencephalopathy 
syndrome, grade 4 allergic reaction, grade 2 or higher arterial thrombosis, grade 4 
hypertension, nephrotic syndrome, hemorrhage of grade 2 or higher in the central nervous 
system or > grade 2 elsewhere, wound dehiscence requiring intervention, perforation of 
gastrointestinal track, or any other grade 3 or 4 clinically significant adverse event 
attributable to bevacizumab that did not resolve in 4 weeks of holding drug (grade 3) or had 
not resolved to grade 1 and with approval of study chair (grade 4).
Post-operative radiation therapy was not permitted. Patients were seen at least every 3 weeks 
with a full physical examination including blood pressure and laboratory studies (including a 
complete blood count and comprehensive metabolic panel) and assessment for adverse 
events during the period of chemotherapy administration.
Patients on Arm B were required to have visits with physical examination, adverse event 
assessments and laboratory studies every 6 weeks while receiving single agent bevacizumab. 
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All patients were followed for recurrence with chest imaging (radiograph or computed 
tomography which were reviewed locally) and physical examination every 3 months for 2 
years, then every 6 months through year 5, then annually through year 10.
Outcomes
The primary objective of this phase III study was to compare the overall survival in patients 
with NSCLC randomised to chemotherapy with bevacizumab (Arm B) and without 
bevacizumab (Arm A) in an intent-to-treat analysis. Overall survival was defined as the time 
from randomisation to death from any cause, and patients who were thought to be alive at 
the time of final analysis were censored at the last date of contact. Secondary objectives 
included disease-free survival as well as toxicity assessment defined as toxicity with 
chemotherapy with or without bevacizumab used in the adjuvant setting in patients with 
resected NSCLC. Other secondary objectives, included to perform analyses of tissue and 
blood to establish factors that predict for clinical outcome in patient receiving chemotherapy, 
with or without bevacizumab, for resected early stage NSCLC. To determine whether 
smoking status is linked to outcome for patients with resected early stage NSCLC treatment 
with chemotherapy with or without bevacizumab in the adjuvant setting.
Statistical analysis
All analyses were conducted on an intent to treat basis. All randomised patients were 
included in the primary analyses and DFS analysis. For toxicity data, only patients who 
received therapy were included. All patients were otherwise assessable. The randomisation 
was stratified based on planned chemotherapy backbone (cisplatin/vinorelbine, cisplatin/
docetaxel, cisplatin/gemcitabine, cisplatin/pemetrexed); stage of disease (IB (≥4 cm), II, 
IIIA-N2, IIIA-T3N1); histology (squamous cell, non-squamous NSCLC); and sex (male or 
female), using permuted blocks within strata with dynamic balancing on main ECOG 
institutions plus affiliates. The statistical design targeted an overall survival (OS) hazard 
ratio (HR) or 0.79 with 85% power while maintaining a significance level of 2·5% in a one-
sided test. Assuming exponential event times, the corresponded to an improvement in the 
median OS of 66 months on Arm A to 83.5 months on Arm B. The total planned accrual 
goal was 1500 patients with full statistical information at 676 deaths.
The study design specified interim analyses starting at 25% information (167 events) and 
every 6 months thereafter with stopping rules defined for efficacy with a truncated O’Brien-
Fleming boundary and for futility with repeated confidence intervals. The study was 
continuously monitored for toxicity signals, particularly the rates of grade 3–5 arterial 
thromboembolic events and bleeding events, as well as the rate of grade 4–5 wound healing 
complications.
OS was defined as the time from randomisation to death from any cause, and patients who 
were thought to be alive at the time of final analysis were censored at the last date of contact. 
Disease-free survival (DFS) was defined as the time from randomisation to an event defined 
as disease recurrence, new primary of lung cancer, second primary, or death, whichever 
occurred first. Patients who did not experience a DFS event at analysis were censored at 
Wakelee et al. Page 7
Lancet Oncol. Author manuscript; available in PMC 2018 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
their last date of disease assessment. Time to treatment discontinuation was measured in 
months from date of registration to date off treatment.
Event-time distributions were estimated using the Kaplan-Meier method. Cox proportional 
hazards models stratified on the randomisation stratification factors were used to estimate 
the hazard ratios and to test for differences between treatment arms. Adverse events, 
reported using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 
4·0, were compared using the Fisher’s exact test; cumulative incidence of treatment 
discontinuation was estimated using a competing risks model.13 All reported P values are 
two-sided, and CIs are at the 95% level. R version 2.10.0 was used for statistical analyses. 
This study is registered with ClinicalTrials.gov, NCT00324805.
Role of the funding source
Funding for this trial was provided by the National Cancer Institute of the National Institutes 
of Health of the United States and was coordinated by the ECOG-ACRIN Cancer Research 
Group Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs). The 
funds were provided to ECOG-ACRIN to support protocol development and conduct 
including auditing and data analysis. The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and had final responsibility for the decision 
to submit for publication.
RESULTS
Between study activation on June 1, 2007 and enrollment termination on September 20, 
2013, a total of 1501 patients were enrolled across the United States National Clinical Trials 
Network (NCTN) and the Cancer Clinical Trials Group (formerly NCIC-CTG). All 1501 
patients are included in the OS and DFS analyses, which were done on an intent to treat 
basis. Twenty-nine patients never started assigned therapy (12 on Arm A and 17 on Arm B) 
as noted in the study Consort Diagram (Figure 1 due to treatment refusal (N=14), 
ineligibility (N=4), progression before start of therapy (N=4), other medical issue (N=7)). A 
total of 234 patients (15·6%, 121 on Arm A and 113 on Arm B) were deemed ineligible 
most commonly for inadequate nodal sampling (N=101) or ineligible stage (N=44). Other 
reasons for ineligibility were registration < 6 weeks from surgery (N=45), elevated baseline 
blood pressure or inadequate documentation of baseline blood pressure (N=15), baseline 
UPC not obtained in time frame (N=20), history of malignancy (N=2), inadequate renal 
function (N=2) and a variety of individual reasons including incorrect pathology, history of 
infarction, active claudication, missing baseline performance status, history of prior 
chemotherapy. The majority of these were identified as ineligible on retrospective central 
review after initiating (and most commonly after completing) therapy. As was standard on 
ECOG-ACRIN trials during the time of enrollment on E1505, neither centralized screening 
nor pre-screening strategies were utilized. The median follow-up on patients still alive was 
50·3 months (IQR 32.9–68.0)(51·7 mos (IQR 34.7–68.9) on Arm A and 48·1 (IQR31.1–
67.0) mos on Arm B).
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Patient demographics and disease characteristics were well balanced by treatment Arm and 
are summarized in Table 1. Of the full 1501 randomized patients (749 on arm A with 
chemotherapy alone and 752 on arm B with the addition of bevacizumab), a majority of the 
patients were white and 50% (N=746) were male. Squamous cell histology was reported for 
28% (N=422) of patients (29% (N= 216) Arm A and 27% (N=206) Arm B). The largest 
proportion of patients (44%, N=636) had stage II disease with 26% (N=383) stage IB and 
30% (N=439) stage IIIA. The vast majority of patients were treated with a lobectomy (77% 
(N=577/749) Arm A, 74% (N=557) Arm B) and 11% (N=81) on Arm A had a 
pneumonectomy compared to 14% (N=103) on Arm B. Systematic lymph node sampling 
was reported for 46% (N=689) of patients on trial and a complete mediastinal lymph node 
dissection was reported for 46% (N=346) Arm A and 47% (N=355) of Arm B. When 
compared to data used as stratification factors, on-study reporting of chemotherapy choice 
was discordant in 0·7% (10/1500 cases with data); pathologic subtype was discordant in 
3·7% (55/1500 cases with data); sex was discordant in 0·5% (8/1501 cases with data); and 
stage was discordant in 14·1% (206/1458 cases with data).
All chemotherapy options were utilized with 25% (N=377) of patients receiving cisplatin/
vinorelbine, 23% (N=343) cisplatin/docetaxel, 19% (N=283) cisplatin/gemcitabine, and 33% 
(N=497) cisplatin/pemetrexed. The median number of treatment cycles was 4 on Arm A 
(range: 1–4; IQR: 4-4) and 9 on Arm B (range: 1–18; IQR: 4–17) (IQR = Interquartile 
Range). The majority of patients on Arm A (81·3%, N=599/737) completed therapy per 
protocol (4 cycles or approximately 3 months), however only 36·6% (N=269/735) of 
patients on Arm B completed all planned therapy (a total of 12 months of therapy). The 
number of patients who discontinued therapy for adverse events on arm A was 62/737 
(8.4%) compared to 203/735 (27.6%) on arm B. The remaining patients came off trial for 
early progression (N= 7 and 35 on arms A and B respectively), patient decision to withdraw 
(N=51/737 (6.9%) and 174/735 (23.7%) on arms A and B respectively), and other issues 
such as alternative therapy, and other complicating disease (N= 27/737 (3.7%) and 54/735 
(7.3%) on arms A and B respectively). In interpreting these results it is critical to bear in 
mind that arm A patients were only on therapy for up to 3 months, compared with up to 12 
months with bevacizumab on arm B. All patients who received any therapy were included in 
the toxicity analyses (N=1473, 738 on Arm A and 735 on Arm B). The reporting of grade 1 
events was not required per protocol. Reporting of grade 2 events that were unexpected and 
related was required, but given uncertainty about expected toxicity with bevacizumab in the 
adjuvant setting, and the fact that only arm B patients were considered to be receiving an 
investigational agent, toxicity reporting was skewed towards arm B. A table of grade 1 and 2 
events that were reported in at least 10% of patients is included (Table 2), but all listed 
events (anemia, fatigue, creatinine increased and decreased neutrophil count) are expected 
events with platinum based chemotherapy. All post-baseline grade 3–5 adverse events of any 
attribution that occurred in at least 1% of patients are included in Table 3. Full details of 
post-baseline grade 3–5 adverse events of any attributions are available in the Supplemental 
materials (pages 6–10). Adverse events associated with anti-angiogenic therapy such as 
hypertension were more common for patients treated with bevacizumab. Statistically 
significantly increased grade 3–5 toxicities of note (all attributions) included: overall worst 
grade (ie all grade 3/4/5 toxicities) (67%(N=496) versus 83%(N=610)); hypertension (8%
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(N=60) versus 30%(N=219)), and neutropenia (33%(N=241) versus 37%(N=275)) on Arms 
A and B, respectively. There was no significant difference in deaths while on treatment per 
arm (N=15 on arm A and N=19 on arm B) (supplemental material page 11). Of the 15 
deaths on arm A, only 3 (thromboembolic event, stroke and sepsis) were considered at least 
possibly related to therapy. Of the 19 deaths on arm B, 10 were considered at least possibly 
related (multiorgan failure, febrile neutropenia, sudden death, myocardial infraction, 
bronchopulmonary hemorrhage, aspiration, bronchopleural fistula, wound dehiscence, lung 
infection (N=2)). Other causes of death that were not considered related were on arm A: 
atrial fibrillation, death (or sudden death) NOS (N=6), thromboembolic death, adult 
respiratory distress syndrome, other neoplasm, respiratory failure, other cardiac disorder. For 
arm A the non-related causes of death were: death NOS (N=5), myocardial infraction, 
hypoxia, sepsis, other neoplasm.
After the 6th planned interim analysis, the independent data safety and monitoring 
committee recommended release of the study results since the repeated confidence interval 
(A/B) (0·77 – 1·33) barely included the alternative of interest, and because the estimated 
conditional power of the trial was estimated to be 4·1% (standard error = 0·006). At previous 
interim analyses, early stopping criteria for efficacy and futility were not met. The results 
reported here include data after 475 survival events (241 on Arm A and 234 on Arm B); this 
represents 70% (475/676) of the planned full information for the final analysis and is 
considered the final analysis. The estimated median OS on Arm A has not been reached; for 
Arm B it was 85·8 mos (74·9 - NA). The estimated OS hazard ratio (B/A) was 0·99 (95% CI: 
0·82–1·19, p=0·90). Figure 2A illustrates OS by treatment arm for the primary analysis 
(ITT) population while Figure 2B is OS in a sensitivity analysis among eligible patients 
(n=1267) demonstrating similar results. A forest plot of OS hazard ratios for various 
subgroups is displayed in Figure 3.
A total of 724 patients have experienced a recurrence or death (DFS event) (360 on Arm A 
and 364 on Arm B). The estimated median DFS and corresponding 95% CI on each 
treatment arm was 42·9 mos (36·7–57·0 mos) on Arm A and 40·6 mos (35·5–49·5 mos) on 
Arm B. Figure 4A displays DFS by treatment arm for the primary analysis (ITT) population. 
A sensitivity analysis among eligible patients (n=1267) was conducted with similar results 
and are displayed in Figure 4B. The estimated DFS hazard ratio (B/A) was 0·99 (95% CI: 
0·86–1·15, p=0·95). For DFS, the forest plot of hazard rations for various subgroups is 
displayed in Figure 5. A total of 607 recurrences were reported and 56·5% (342/605) of 
them were biopsied. Sites of recurrence were reported as follows: lung (n=299, 37%), liver 
(n=40, 5%), central nervous system (n=122, 15%), subcutaneous and lymph node (n=126, 
16%), skeletal (n=113, 14%), other sites (n=110, 14%), and unknown site (n=1). More than 
one site could have been reported at the time of a recurrence.
The DFS and OS results across all stratification factors including stage, sex, and histology 
appear consistent with the overall outcomes of the study. The subset analysis by 
chemotherapy is immature at this time with the median follow-up by chemotherapy choice at 
54·3 months (IQR 34.7–71.5) on vinorelbine, 60·3 months (IQR 41.2–76.0) on docetaxel, 
57·0 months (IQR 36.4–71.4) on gemcitabine, and only 40·6 months (IQR 29.3–52.9) on 
pemetrexed.
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DISCUSSION
The addition of bevacizumab to four cycles of adjuvant cisplatin based chemotherapy for 
resected early stage NSCLC failed to improve OS, the primary endpoint of this trial. The 
estimated OS hazard ratio (B/A) was 0·99 (95% CI: 0·82–1·19, p=0·90). Thus, four cycles of 
cisplatin based adjuvant chemotherapy remains the standard of care for patients with 
resected stage II and IIIA NSCLC and is also considered for many patients with resected 
stage IB NSCLC with larger tumors (at least 4 centimeters in size). Though bevacizumab 
has improved response rate, PFS, and survival in advanced non-squamous NSCLC when 
combined with carboplatin/paclitaxel10 an OS benefit was not seen when bevacizumab was 
combined with other platinum doublets for advanced stage NSCLC, most notably with 
cisplatin/gemcitabine in the AVAiL trial.14 The results of E1505 demonstrate that the 
addition of bevacizumab to adjuvant chemotherapy failed to improved outcomes in patients 
with resected NSCLC, as it has also failed with adjuvant regimens for colon cancer15–17, 
breast cancer18, and melanoma.19
The median overall survival of E1505 was 85·6 months for patients on Arm B and in excess 
of 85 months for Arm A, although this could change with longer follow-up (median follow-
up not mature). However, these survival results appear to surpass the median OS of 65·7 
months reported in the ANITA adjuvant trial, which served as our control arm estimate for 
this trial. The survival difference is nearly 20 months despite the fact that bevacizumab was 
not additive, and thus patients received no other therapeutic intervention beyond that given 
on ANITA. The DFS in our trial was 40·6 months on Arm B and 42·9 months on Arm A 
versus 36·3 months DFS on the ANITA trial, a difference of 7 months at most. Thus, the 
relative OS benefit seen on E1505 is far in excess of the DFS change seen over time between 
the two trials. Likely this in part reflects careful selection of patients with better imaging 
modalities available to detect more advanced stage disease prior to resection, and also the 
availability of more modalities to treat patients who have recurred or perhaps the use of 
modern chemotherapy regimens in this study. Completion of four cycles of adjuvant 
chemotherapy was higher on E1505 than ANITA, which may also have contributed. Though 
any comments on why completion of chemotherapy was higher on E1505 than ANITA is 
highly speculative, it may be related to better tolerability of the newer chemotherapeutic 
options and also to improved supportive medications. ANITA did also have a slightly higher 
proportion of stage IIIA patients (>35% compared to ~30% on E1505) but that was offset by 
a high percentage of stage I patients as well (36% on ANITA versus 25% on E1505).
The potential reasons behind the lack of survival benefit in early stage disease with 
bevacizumab could be attributed to the relatively modest therapeutic effects of this agent in 
advanced stage disease, lack of predictive biomarkers for patient selection, and activation of 
alternative biological pathways to promote angiogenesis. Biomarker analyses from tumor 
samples of patients enrolled to E1505 are planned to understand the biology underlying 
disease recurrence, and to determine whether a sensitive subset to bevacizumab could be 
identified.
Limitations of this trial include the prolonged enrollment period, the high percentage of 
ineligible patients, and emerging data over the course of the trial that bevacizumab in 
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subsequent trials in advanced stage NSCLC and in the adjuvant setting with other 
malignancies did not perform at the level envisioned based on the E4599 results. The lack of 
a biomarker for bevacizumab was another significant limitation that prevented us from 
identifying a patient population who may have benefitted from adjuvant bevacizumab.
E1505 was not designed to compare chemotherapy regimens and at this point no clear 
differences have emerged yet. However, follow-up is limited particularly with the cisplatin/
pemetrexed group as that regimen was added later in the trial. Longer follow-up and 
additional detailed analyses of these data accounting for potential imbalances in prognostic 
factors between treatment arms within the subgroups are needed before any conclusions of 
an effect of chemotherapy choice on outcomes can be made. The ongoing JIPANG trial 
(UMIN000006737) in Japan is randomizing 800 patients with resected NSCLC to cisplatin/
pemetrexed versus cisplatin/vinorelbine and will provide prospective data to answer the 
question of whether or not there are meaningful differences in outcomes with these two 
chemotherapy doublets. We also did not find any meaningful differences in subgroup 
analyses, but hope that as the molecular analyses and other correlative work with the tissue 
and blood samples collected on the trial is completed that it may shed some light on relevant 
biologic markers that can help in the better defining which patients are most likely to benefit 
from adjuvant chemotherapy.
Areas of ongoing research for adjuvant treatment of advanced stage NSCLC include targeted 
tyrosine kinase inhibitor use in patients with resected NSCLC harboring an activating 
mutation in the epidermal growth factor receptor (EGFR) or translocation in anaplastic 
lymphoma kinase (ALK), but this is a small subset of patients. The PD-1 checkpoint 
inhibitors nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab are 
approved for the second-line treatment of advanced stage NSCLC, with recent positive data 
in first-line metastatic disease for a subset of patients. Phase III trials are ongoing with each 
of these agents, as well as similar check point inhibitors, as adjuvant therapy for resected 
early stage NSCLC. E1505 provides definitive evidence that bevacizumab should not be 
used in the adjuvant setting for resected early stage NSCLC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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PANEL: RESEARCH IN CONTEXT
Evidence before this study
In developing the study design and protocol, we did a systematic review of the scientific 
literature. We searched PubMed, with no time restrictions; abstracts of major oncology 
meetings; and trial websites, including ClinicalTrials.gov, for preclinical data and clinical 
trials (phase I, II, III) published in English that assessed patients with non-small-cell lung 
cancer (NSCLC) who were treated with adjuvant chemotherapy, and also searched for 
studies with bevacizumab in the context of metastatic NSCLC, and in the adjuvant setting 
for any malignancy. We used the search terms: lung cancer, NSCLC, adjuvant 
chemotherapy, peri-operative chemotherapy, neo-adjuvant chemotherapy, adjuvant 
therapy, post-operative chemotherapy, neo-adjuvant chemotherapy, adjuvant therapy, 
bevacizumab. Clinical data in support of this trial included phase 3 trials demonstrating a 
survival benefit in NSCLC patients who were treated with adjuvant chemotherapy after 
surgical resection and phase 3 trials demonstrating a response rate and progression free 
survival benefit with the addition of bevacizumab to platinum doublet chemotherapy in 
patients with metastatic NSCLC. An overall survival benefit with the addition of 
bevacizumab was demonstrated in the E4599 trial, in which the agent was added to first-
line carboplatin and paclitaxel chemotherapy in patients with metastatic NSCLC. Based 
on the survival benefit seen with adjuvant platinum doublet chemotherapy after surgical 
resection in early stage NSCLC and the survival benefit seen with the addition of 
bevacizumab to platinum doublet chemotherapy in metastatic disease, we postulated that 
the addition of bevacizumab to platinum doublet adjuvant chemotherapy in early stage 
NSCLC would result in a survival benefit.
Added value of this study
Our study demonstrated that despite the additive benefit of bevacizumab to platinum 
doublet chemotherapy in patients with metastatic lung cancer, no differences in disease 
free survival or overall survival were seen on the bevacizumab arm of this trial in patients 
with resected early stage NSCLC. We did not identify any subsets of patients with benefit 
or any with unexpected harm with the combination.
Implications of all the available evidence
Based on the results of this trial the use of bevacizumab as a post-operative adjuvant 
regimen in patients with NSCLC is not advised. During the period of time of the study 
conduct and analysis adjuvant trials of bevacizumab in other malignancies were reported 
and were similarly negative for any benefit in overall survival. The overall outcomes of 
this trial did demonstrate an improvement in overall survival compared to historical 
controls, reflecting other improvements in lung cancer outcomes for patients with 
resected early stage NSCLC.
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Figure 1. 
Trial Profile
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Figure 2. 
Figure 2A: Overall survival by treatment arm for the primary analysis population (n=1501)
Figure 2B: Overall survival by treatment arm among eligible patients (n=1267)
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Figure 3. 
A forest plot of overall survival hazard ratios for various subgroups
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Figure 4. 
Figure 4A: Disease-free survival by treatment arm for the primary analysis population 
(n=1501)
Figure 4B: Disease-free survival by treatment arm for the eligible patient population 
(n=1267)
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Figure 5. 
A forest plot of DFS hazard ratios for various subgroups
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Table 1
Demographics
Patient Characteristics
Arm A (Chemo)
n=749
Arm B (Chemo + Bev)
n=752
Age (Median) Years 61 (IQR 55,67) 61(IQR 54,67)
Sex Male 375/749 (50%) 371/752 (49%)
Female 374/749 (50%) 381/752 (51%)
Race White 642/746 (86%) 660/746 (88%)
Black 74/746 (10%) 57/746 (8%)
Asian 22/746 (3%) 16/746 (2%)
Native Hawaiian 3/746 (<1%) 2/746 (<1%)
Native American 1/746 (<1%) 5/746 (1%)
Not reported 4/746 (1%) 6/746 (1%)
Chemo Regimen Cisplatin/vinorelbine 187/749 (25%) 190/751 (25%)
Cisplatin/Docetaxel 172/749 (23%) 171/751 (23%)
Cisplatin/gemcitabine 142/749 (19%) 141/751 (19%)
Cisplatin/pemetrexed 248/749 (33%) 249/751 (33%)
Histology Squamous 216/749 (29%) 206/751 (27%)
Adenocarcinoma 424/749 (57%) 450/751 (60%)
Large Cell 22/749 (3%) 16/751 (2%)
Other/Mixed 87/749 (12%) 79/751 (11%)
Stage (AJCC6) IB T2N0 197/728 (27%) 186/730 (25%)
IIA T1NI 83/728 (11%) 91/730 (12%)
IIB T2N1 197/728 (27%) 197/730 (27%)
IIB T3N0 27/728 (4%) 41/730 (6%)
IIIA T3N1 29/728 (4%) 32/730 (4%)
IIIA T1–3 N2 195/728 (27%) 183/730 (25%)
Surgery Pneumonectomy 84/749 (11%) 108/751 (14%)
Lobectomy 577/749 (77%) 557/751 (74%)
Bilobectomy 59/749 (8%) 46/751 (6%)
Complex lobectomy, Other 29/749 (4%) 40/751 (5%)
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Table 2
Grade 1–2 events occurring in >=10% of patients
Arm A Arm B
Toxicity Type N(%) N(%)
Anemia 273 (37%) 202 (27%)
Fatigue 72 (10%) 77 (10%)
Creatinine increased 195 (26%) 276 (38%)
Neutrophil count decreased 243 (33%) 261 (36%)
WORST DEGREE 525 (71%) 567 (77%)
Anemia 273 (37%) 202 (27%)
Note: Grade 1 events were not reportable; grade 2 events were reportable only if deemed possibly related to bevacizumab treatment and 
unexpected.
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